Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of nicotinamide compound in preparation of medicine for treating herpes simplex encephalitis

A nicotinamide, herpes simplex technology, applied in the field of medicine, can solve the problems of mutagenicity, drug resistance, seriousness, etc., and achieve the effects of improving the symptoms of encephalitis, inhibiting the infection of encephalitis, and weakening the inflammatory response

Pending Publication Date: 2022-02-08
JINAN UNIVERSITY
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is currently no effective vaccine against herpes simplex encephalitis caused by HSV-1, and the clinically used therapeutic drugs are mainly nucleoside analogues such as acyclovir (ACV) and valacyclovir (Famciclovir, FCV). , although such drugs can effectively inhibit viral infection, they are mutagenic and drug resistance is becoming more and more serious

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of nicotinamide compound in preparation of medicine for treating herpes simplex encephalitis
  • Application of nicotinamide compound in preparation of medicine for treating herpes simplex encephalitis
  • Application of nicotinamide compound in preparation of medicine for treating herpes simplex encephalitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1 Niacinamide, nicotinic acid, nicotinamide nitrogen oxide comprehensive antiviral ability in vitro

[0031] The structural formulas of nicotinamide (compound 2, Nicotinamide), nicotinic acid (compound 5, Nicotinic acid), and nicotinamide nitrogen oxide (compound 1, Nicotinamide N-oxide) are as follows:

[0032]

[0033] Will 2×10 5 N2a was inoculated in 12-well plates, which were placed in 5% CO 2 , Cultivated overnight in a cell incubator at 37°C; the cells were divided into blank control group (cell), virus control group (HSV-1), nicotinamide-treated virus group (40 μM, 80 μM and 160 μM), niacin-treated virus group (40 μM , 80 μM and 160 μM) and nicotinamide nitrogen oxide treated virus groups (40 μM, 80 μM and 160 μM), after 12 hours of co-treatment with the drug and the virus, the viral DNA was extracted to detect the effect of the drug on the copy number of the viral DNA level, and the results were as follows figure 1 shown;

[0034] Depend on figur...

Embodiment 2

[0035] Example 2 Niacinamide, nicotinic acid, and nicotinamide nitrogen oxide inhibit the adsorption process of viruses

[0036] The structural formulas of nicotinamide (compound 2, Nicotinamide), nicotinic acid (compound 5, Nicotinic acid), and nicotinamide nitrogen oxide (compound 1, Nicotinamide N-oxide) are as follows:

[0037]

[0038] Will 2×10 5 N2a was inoculated in a 12-well plate, and the culture plate was placed in 5% CO 2 , Cultivated overnight in a cell incubator at 37°C; the cells were divided into blank control group (cell), virus control group (HSV-1), nicotinamide-treated virus group (40 μM, 80 μM and 160 μM), nicotinic acid-treated virus group (40 μM , 80 μM and 160 μM) and nicotinamide nitrogen oxide treatment virus group (40 μM, 80 μM and 160 μM), the culture plate was placed at 4 ° C, after the drug and virus were co-incubated for 80 min, the supernatant was discarded, 500 μL of medium was added, and placed in 5%CO 2 , 37 ℃ cell incubator to continue...

Embodiment 3

[0040]Example 3 Niacin prevents HSV-1 infection test

[0041] The structural formula of nicotinamide (compound 2, Nicotinamide) is as follows:

[0042]

[0043] Will 2×10 5 N2a was inoculated in a 12-well plate, and the culture plate was placed in 5% CO 2 , Cultivated overnight in a 37°C cell incubator; the cells were divided into blank control group (cell), virus control group (HSV-1), and nicotinamide nitrogen oxide (40 μM) pretreated virus group; 40 μM nicotinamide nitrogen oxide The pretreatment virus group was pretreated with drugs for 3 hours, and then the drugs were discarded. After 12 hours of virus infection, the virus DNA was extracted and the copy number of the virus DNA was detected. The results are as follows: image 3 shown;

[0044] Depend on image 3 The results showed that compared with the virus group, the viral DNA copy number of the virus group treated with 40 μM nicotinamide nitrogen oxide was significantly reduced, indicating that this type of drug...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicines, in particular to application of a nicotinamide compound in preparation of a medicine for preventing or treating herpes simplex encephalitis. The medicine can remarkably inhibit encephalitis infection induced by herpes simplex virus, and in-vitro and in-vivo experiments show that the antiviral mechanism of the medicine is virus adsorption inhibition, the medicine can remarkably inhibit expression of virus genes and virus proteins, meanwhile, the medicine can effectively inhibit expression of inflammation-related genes induced by the virus, inflammatory response is weakened, the symptom of herpes simplex encephalitis is improved, and a new strategy is provided for developing antiviral drug-resistant strain drugs.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of nicotinamide compounds in the preparation of medicines for treating herpes simplex encephalitis. [0002] technical background [0003] Herpes simplex virus I type (Herpes simplex virus I type, HSV-1) belongs to the alpha herpes virus subfamily, is a DNA virus, and is a common human neurotropic virus. The virus primarily causes infections of the corners of the mouth, eyes, and brain, leading to herpetic gingivostomatitis, keratitis, and fatal herpes simplex encephalitis. At the same time, the virus can be latent in the trigeminal ganglion, and local trauma, immunosuppression, hormone fluctuations, and emotional depression can activate the virus. In 2015, the World Health Organization (WHO) estimated the global herpes simplex virus type 1 (HSV-1) infection for the first time, and more than 3.709 billion people (aged 0-49 years) were infected with HSV-1 worldwid...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/455A61K31/706A61K31/7084A61P31/22A61P25/00
CPCA61K31/455A61K31/706A61K31/7084A61P31/22A61P25/00Y02A50/30
Inventor 王一飞宋小威任哲李风曹文彦廖晓凤
Owner JINAN UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com